Harold Brakewood - Immuneering Corp Chief Officer
| IMRX Stock | USD 2.10 0.01 0.47% |
Executive
Harold Brakewood is Chief Officer of Immuneering Corp
| Age | 58 |
| Address | 245 Main Street, Cambridge, MA, United States, 02142 |
| Phone | 617 500 8080 |
| Web | https://immuneering.com |
Harold Brakewood Latest Insider Activity
Tracking and analyzing the buying and selling activities of Harold Brakewood against Immuneering Corp stock is an integral part of due diligence when investing in Immuneering Corp. Harold Brakewood insider activity provides valuable insight into whether Immuneering Corp is net buyers or sellers over its current business cycle. Note, Immuneering Corp insiders must abide by specific rules, including filing SEC forms every time they buy or sell Immuneering Corp'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Harold Brakewood over three months ago Acquisition by Harold Brakewood of 165000 shares of Immuneering Corp at 9.71 subject to Rule 16b-3 |
Immuneering Corp Management Efficiency
The company has return on total asset (ROA) of (0.3742) % which means that it has lost $0.3742 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6181) %, meaning that it created substantial loss on money invested by shareholders. Immuneering Corp's management efficiency ratios could be used to measure how well Immuneering Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.59 in 2024. Return On Capital Employed is likely to drop to -0.65 in 2024. At this time, Immuneering Corp's Non Currrent Assets Other are fairly stable compared to the past year. Other Assets is likely to rise to about 898 K in 2024, whereas Total Assets are likely to drop slightly above 97.7 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Barbara JD | Kronos Bio | 65 | |
| JD Esq | Centessa Pharmaceuticals PLC | N/A | |
| Jim Jacobson | NewAmsterdam Pharma | N/A | |
| Sandra Gardiner | Kronos Bio | 58 | |
| Allison Nance | Lyra Therapeutics | N/A | |
| Mario Orlando | Gossamer Bio | N/A | |
| Ray Knox | Lyra Therapeutics | N/A | |
| Magnus DPHIL | Monte Rosa Therapeutics | N/A | |
| Rebecca Cohen | Ikena Oncology | N/A | |
| Samantha Vuksanic | Ikena Oncology | N/A | |
| John Bishop | Lyra Therapeutics | 62 | |
| Gloria Cosgrove | Lyra Therapeutics | N/A | |
| Pamela Esposito | Replimune Group | 50 | |
| Binh Vu | Pmv Pharmaceuticals | N/A | |
| Bob Rambo | NewAmsterdam Pharma | N/A | |
| Lisa Nolan | Gossamer Bio | 62 | |
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
| Marc MD | NewAmsterdam Pharma | 57 | |
| Neil CPA | Compass Therapeutics | 57 | |
| Paul Bullock | Replimune Group | N/A | |
| Christopher Sarchi | Replimune Group | 55 | |
Management Performance
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.37 |
Immuneering Corp Leadership Team
Elected by the shareholders, the Immuneering Corp's board of directors comprises two types of representatives: Immuneering Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immuneering. The board's role is to monitor Immuneering Corp's management team and ensure that shareholders' interests are well served. Immuneering Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immuneering Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dr MBA, President CoFounder | ||
| Mallory CPA, Principal Fin | ||
| Praveen Nair, Head VP | ||
| Mohamedi MBA, Head Devel | ||
| Leah Neufeld, Chief Officer | ||
| Brett Hall, Chief Officer | ||
| Harold Brakewood, Chief Officer | ||
| Paula CPA, Director Controller | ||
| Scott MD, Chief Officer | ||
| Peter King, Head VP | ||
| MS MBA, CoFounder Emeritus | ||
| Michael JD, Chief Secretary | ||
| MBA MBA, President, CoFounder | ||
| Rajaraman Krishnan, Head Discovery |
Immuneering Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immuneering Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | 19.1 M | ||||
| Shares Outstanding | 31.05 M | ||||
| Shares Owned By Insiders | 29.12 % | ||||
| Shares Owned By Institutions | 30.11 % | ||||
| Number Of Shares Shorted | 2.05 M | ||||
| Price To Book | 1.14 X | ||||
| Price To Sales | 563.62 X | ||||
| Revenue | 455 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immuneering Stock Analysis
When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.